Related Experiment Video
Updated: Oct 1, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
LC determination of oxcarbazepine and its active metabolite in human serum
1EPSM Lille-métropole Hospital, 109 rue du Général Leclerc, Lille, Armentières, France.
Abstract:
Twenty-five percent of epileptic patients present refractory seizures to current frontline antiepileptic drugs, needing new treatments and leading to the introduction of several new AEDs, among which is oxcarbazepine (Trileptal). This 10-ketoanalogue of carbamazepine seems to be a weaker inducer of cytochrome P450 3A4. However, pharmacokinetic interactions with clinical significance have already been reported, before the marketing of Trileptal in France. The aim of this study was to develop and validate a HPLC method allowing simultaneous dosage of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn. After plasma defecation by acetonitrile, dosage was obtained by analysis of the supernatants on a C(18) reversed-phase column coupled with UV detection (240 nm). The statistical validation was performed according to the recommendations of a European technical commission. This method seems to provide a quite good selectivity from the psychotropic therapeutics, which is commonly coprescribed with AEDs. Linearity was established for the whole concentration range, whatever the compound. Quantization limits of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn are 0.58, 3.5, 2.35, 0.66, 1.02 and 3.13 microg/ml, respectively, and absolute recoveries are 105.15, 84.76, 94.45, 96.52, 98.62 and 95.08%, respectively.
Insights
A new HPLC method accurately measures oxcarbazepine and other antiepileptic drugs in plasma. This validated assay is crucial for managing refractory epilepsy patients on multiple medications.
Area of Science:
- Pharmacology
- Analytical Chemistry
- Clinical Pharmacy
Background:
- Refractory epilepsy affects 25% of patients, necessitating novel antiepileptic drugs (AEDs).
- Oxcarbazepine, a carbamazepine analog, is a newer AED with potential pharmacokinetic interactions.
- Accurate drug monitoring is essential for optimizing treatment and managing polypharmacy in epilepsy.
Purpose of the Study:
- To develop and validate a high-performance liquid chromatography (HPLC) method for simultaneous quantification of key antiepileptic drugs.
- To establish a reliable analytical tool for therapeutic drug monitoring of oxcarbazepine and related compounds.
Main Methods:
- Plasma samples were treated with acetonitrile for protein precipitation.
- Analysis was performed using a C18 reversed-phase column with UV detection at 240 nm.
- Method validation followed European technical commission recommendations, assessing selectivity, linearity, quantification limits, and recovery.
Main Results:
- The HPLC method demonstrated good selectivity for oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital, and phenytoin.
- Linearity was achieved across the entire concentration range for all compounds.
- Quantification limits ranged from 0.58 to 3.5 µg/mL, with absolute recoveries between 84.76% and 105.15%.
Conclusions:
- The validated HPLC method provides accurate and reliable simultaneous measurement of essential antiepileptic drugs.
- This assay is suitable for therapeutic drug monitoring in epilepsy patients, particularly those on oxcarbazepine and potentially interacting comedications.
- The method supports clinical management by enabling precise quantification of AED levels in complex treatment regimens.
Related Concept Videos
Drug Concentrations: Measurements
Plasma —...
Drug Concentration Versus Time Correlation
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the lowest drug...
Time Course of Drug Effect
